KOPRAN vs NEULANDLAB: Stock Comparison

Kopran Limited vs Neuland Laboratories Limited

Live data: 29 May 2026, 4:01 PM IST • Source: NSE and company filings

Neuland Laboratories Limited is the larger company by market capitalisation. Kopran Limited shows a lower P/E and a higher dividend yield, while Neuland Laboratories Limited shows a higher ROE, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Kopran Limited and Neuland Laboratories Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, KOPRAN is more favourable on 3 of 13 scored metrics and NEULANDLAB on 10These counts are context-free and are not an overall rating.

Key Differences

Market Cap
NEULANDLAB is the larger company
₹23,702 Cr vs ₹942 Cr
P/E Ratio
KOPRAN has a lower P/E
38.28x vs 66.58x
P/B Ratio
KOPRAN has a lower P/B
1.86x vs 12.93x
EPS
NEULANDLAB has higher earnings per share
₹293.13 vs ₹3.41
Dividend Yield
KOPRAN has a higher dividend yield
1.59% vs 0.06%
Revenue Growth (TTM YoY)
NEULANDLAB has faster revenue growth
136.4% vs -3.66%
EPS Growth (TTM YoY)
NEULANDLAB has faster EPS growth
664.4% vs -71.88%
Qtr Sales Growth
NEULANDLAB has stronger quarterly sales growth
136% vs -3.03%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricKOPRANNEULANDLAB
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricKOPRANNEULANDLAB
Live Price₹206.27₹18,461
Day Change6.56%-2.3%
Volume38.55 L15,039
52-Week High₹219₹20,089
52-Week Low₹107₹11,500
Distance from 52W High-5.81%-8.1%

Valuation

MetricKOPRANNEULANDLAB
Market Cap₹942 Cr₹23,702 Cr
P/E Ratio38.28x66.58x
P/B Ratio1.86x12.93x
EPS₹3.41₹293.13
Book Value₹107.35₹1,460.02
Dividend Yield1.59%0.06%

Growth

MetricKOPRANNEULANDLAB
Revenue Growth (TTM YoY)-3.66%136.4%
EPS Growth (TTM YoY)-71.88%664.4%
Qtr Sales Growth-3.03%136%
Qtr Profit Growth-32.9%665%

Profitability & Leverage

MetricKOPRANNEULANDLAB
ROE4.85%21.4%
ROCE9.75%26.6%
Net Margin3.78%17.99%
Operating Margin6.58%28.4%
Debt to Equity0.29x0.16x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricKOPRANNEULANDLAB
Promoter Holding44.42%32.63%
FII Holding0.51% 0.06 pp20.46% 0.44 pp
DII Holding0%15.84% 1.13 pp
Public Holding55.06% 0.06 pp31.07% 0.69 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Kopran Limited and Neuland Laboratories Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.